The present invention generally relates to delivery devices for delivering substances such as drugs, vaccines and the like, and more specifically relates to a drug delivery device for injecting such substances intradermally, i.e., into the skin. In addition, the present invention relates to a needle assembly that is adaptable for use with a variety of drug containers such as syringes for making intradermal injections.
A wide variety of hypodermic injection devices are commercially available. Most hypodermic injections are intended to be intramuscular so that the hypodermic needle penetrates through an individual's skin layer and subcutaneous tissue and into the muscle tissue. Under some circumstances, however, limited needle penetration is desired. Under some circumstances, for example, an intradermal injection is desired where the needle does not penetrate beyond the dermis layer.
One technique for administering intradermal injections is known as the Mantoux procedure. A Mantoux procedure is relatively complicated and requires technical skill from the medical professional or individual administering the injection. Additionally, the Mantoux procedure can prove painful for the individual receiving the injection, especially when somebody without experience is administering the injection.
Devices have been proposed for providing intradermal injections, which include shortened needles compared to conventional needle sizes. The smaller needles are not intended to penetrate beyond the dermis layer of the individual. Such devices are shown in U.S. Pat. No. 5,527,288, which issued on Jun. 18, 1996; U.S. Pat. No. 4,886,499, which issued on Dec. 12, 1989; and U.S. Pat. No. 5,328,483, which issued on Jul. 12, 1994. The proposed devices, however are not without shortcomings and drawbacks.
For example, the devices shown in U.S. Pat. Nos. 5,527,288 and 4,886,499 are highly specialized injectors. The designs for these injectors include relatively complex arrangements of components that cannot be economically manufactured on a mass production scale. Therefore, such devices have limited applicability and use.
Similarly, the device shown in U.S. Pat. No. 5,328,483 requires a specially designed injector and, therefore, it is not readily adapted to be used with a variety of syringe types. Additionally, the assembly of that patent is not conducive to economical mass production.
There is need for an intradermal injection device that is suitable for use with a variety of syringe bodies. Additionally, there is a need for an intradermal injection device that can be economically manufactured on a mass production scale. This invention addresses those needs and avoids the shortcomings and drawbacks discussed above.
In contrast to the prior devices discussed above, it has been found that a drug delivery device particularly suited for use in intradermally injecting substances such as drugs, vaccines and the like can be constructed in accordance with the present invention. Specifically, the present invention is directed to a drug delivery device including a needle assembly for use in making intradermal injections. The needle assembly has an adapter that is attachable to prefillable containers such as syringes and the like. The needle assembly is supported by the adapter and has a hollow body with a forward end extending away from the adapter. A limiter surrounds the needle and extends away from the adapter toward the forward end of the needle. The limiter has a skin engaging surface that is adapted to be received against the skin of an animal such as a human. The needle forward end extends away from the skin engaging surface a selected distance such that the limiter limits the amount or depth that the needle is able to penetrate through the skin of an animal.
In addition, the present invention is directed to a method of intradermally injecting at least one substance into the skin including the steps of pressing the needle perpendicularly to the skin of the person to receive an injection, injecting the substance into skin of the person with the depth of penetration of the needle being mechanically limited to the intradermal space by the limiter that surrounds the needle. Also, in the preferred embodiment, the step of pressing the needle perpendicularly to the skin of the person includes orienting the needle perpendicularly to the skin, and the step of injecting the substance either includes moving a plunger that is received within the reservoir or deflecting two sheets of thermoplastic material forming the reservoir toward each other to expel the substance from the reservoir during an injection.
The various features and advantages of this invention will become apparent to those skilled in the art from the following detailed description of the currently preferred embodiments. The drawings that accompany the detailed description can be briefly described as follows.
The needle assembly 20 includes a hub 22 that supports a needle 24. The limiter 26 receives at least a portion of the hub 22 so that the limiter 26 generally surrounds the needle 24 as best seen in
One end 30 of the hub 22 is able to be secured to a receiver 32 of a syringe. A variety of syringe types can be used with a needle assembly designed according to this invention, with several examples being given below. The opposite end of the hub 22 preferably includes extensions 34 that are nestingly received against abutment surfaces 36 within the limiter 26. A plurality of ribs 38 preferably are provided on the limiter 26 to provide structural integrity and to facilitate handling the needle assembly 20.
By appropriately designing the size of the components, a distance d between a forward end or tip 40 of the needle 24 and a skin engaging surface 42 on the limiter 26 can be tightly controlled. The distance d preferably is in a range from approximately 0.5 millimeters to approximately 3 millimeters. When the forward end 40 of the needle 24 extends beyond the skin engaging surface 42 a distance within that range, an intradermal injection is ensured because the needle is unable to penetrate any further than the typical dermis layer of an animal. Typical tissue layers include an epidermis between 50 and 100 micrometers, a dermis layer between 2 and 3 mm then subcutaneous tissue followed by muscle tissue.
As can be best seen in
Regardless of the shape or contour of the skin engaging surface 42, the preferred embodiment includes enough of a surface area that contacts the skin to facilitate stabilizing the injector relative to the animal's skin. In the most preferred arrangement, the skin engaging surface 42 facilitates maintaining the injector in a generally perpendicular orientation relative to the skin surface.
It is important to note that although
Having a hub 22 and limiter 26 provides the advantage of making an intradermal needle practical to manufacture. The preferred needle size is a small gauge hypodermic needle, commonly known as a 30 gauge or 31 gauge needle. Having such a small diameter needle presents a challenge to make a needle short enough to prevent undue penetration beyond the dermis layer of an animal. The limiter 26 and the hub 22 facilitate utilizing a needle 24 that has an overall length that is much greater than the effective length of the needle, which penetrates the individual's tissue during an injection. With a needle assembly designed according to this invention, manufacturing is enhanced because larger length needles can be handled during the manufacturing and assembly processes while still obtaining the advantages of having a short needle for purposes of completing an intradermal injection.
The hub 22 can be secured to the syringe body 62 in a variety of known manners. In one example, an interference fit is provided between the interior of the hub 22 and the exterior of the outlet port portion 72 of the syringe body 62. In another example, a conventional luer fit arrangement is provided to secure the hub 22 on the end of the syringe 60. As can be appreciated from
A receiver 90 includes a generally cylindrical neck portion 92 that preferably is secured to the outlet port 86 using a heating or welding process as known in the art. A flange 94 preferably rests against the body portion 82 of the syringe to provide structural integrity. An extension 96 extends away from the flange 94 in a direction opposite from the cylindrical portion 92. The needle assembly 20 preferably is received within the extension 96 as shown in
The receiver 90 preferably supports a sealing membrane 100 that closes off the outlet port 86 so that the syringe can be prefilled. The needle assembly 20 preferably includes a back end 102 of the needle that penetrates the sealing membrane 100 when the hub 22 is received within the extension 96.
The side walls of the reservoir 84 preferably are squeezed between a thumb and index finger so that the side walls collapse towards each other and the substance within the reservoir 84 is expelled through the opening in the forward end 40 of the needle 24. In the embodiment of
This invention provides an intradermal needle injector that is adaptable to be used with a variety of syringe types. Therefore, this invention provides the significant advantage of facilitating manufacture and assembly of intradermal needles on a mass production scale in an economical fashion.
Operation and Use
Having described the preferred embodiments of the intradermal delivery device 80 of the present, including the needle assembly 20 and drug container 60, its operation and use is described below.
Use of the delivery device to administer substances such as drugs, vaccines and the like into the intradermal layer is significantly easier than with a traditional syringe and needle. Using a traditional syringe and needle is technique-dependent and requires considerable skill to develop an acceptable skin wheal. In particular, the needle must be carefully guided at a shallow angle under the skin while maintaining correct orientation of the needle bevel. In contrast, with a prefilled intradermal delivery device of the present invention, the user simply presses the device perpendicularly on to the skin and injects the substance. The depth of penetration of the needle is mechanically limited to the intradermal space. In this way, there is no need to orient the needle bevel during injection. Orienting the device, particularly the needle, perpendicularly to the skin, as well as stability while injecting the substance, is facilitated by the design of the device.
Referring now to
A supply of syringe barrels 200 includes the desired form of syringe, such as those illustrated and discussed above. A locally controlled environment 202 preferably is maintained in a known manner. The locally controlled environment 202 preferably is situated to immediately accept the syringes without requiring any intermediate cleaning or sterilizing steps between the supply 200 and the environment 202.
In one example, the syringe barrels are washed with air at 204 to remove any particulates from the syringes. The syringes preferably are then coated at 206 with a lubricant such as a lubricating silicone oil on the inner surface. The lubricant facilitates moving the stopper 70 and plunger rod 66 through the syringe during actual use of the device.
The end of syringes that eventually will needle assembly 20 may be capped with a tip cap within the environment 202. In one example, tip caps are supplied at 208. The tip caps are air washed at 210. The cleaned tip caps and syringe barrels are conveyed to an assembly device 212 where the tip caps are secured onto the syringes. The syringe barrel assemblies are then conveyed to a filling station 214 to be filled with the desired substance.
Once filled as desired, the stoppers 70 are inserted into the open end of the syringes at 220. Prior to inserting the stoppers 70, they preferably are assembled with the plunger rods 66 at 222 and lubricated at 224 with a conventional lubricant in a known manner. The assembled, filled syringes preferably are inspected at 226 for defects and discharged from the locally controlled environment.
The syringes typically will be sterilized at 230 and packaged at 232 into individual packages or into bulk packaging depending on the needs of a particular situation. Suitable sterilization techniques are known and will be chosen by those skilled in the art depending on the needs of a particular situation or to accommodate the properties of a given substance. Sterilizing a device designed according to this invention can be completed before or after packaging.
Variations of the filling steps are within the scope of this invention. For example, the stopper can be inserted first, then fill the syringe, followed by applying a tip cap. Additionally, when the device includes a syringe body of the type shown in
The actual insertion of the desired substance into the syringe body can be accomplished in any of several known manners. Example filling techniques are disclosed in U.S. Pat. No. 5,620,425 to Hefferman et al.; U.S. Pat. No. 5,597,530 to Smith et al.; U.S. Pat. No. 5,537,042 to DeHaen; U.S. Pat. No. 5,531,255 to Vacca; U.S. Pat. No. 5,519,984 to Veussink et al.; U.S. Pat. No. 5,373,684 to Veussink et al.; U.S. Pat. No. 5,265,154 to Liebert et al.; U.S. Pat. No. 5,287,983 to Liebert et al.; and U.S. Pat. No. 4,718,463 to Jurgens, Jr. et al., each of which is incorporated by reference into this specification.
The description given above provides example implementations of this invention. Variations and modifications may become apparent to those skilled in the art that do not necessarily depart from the basis of this invention. The scope of legal protection given to this invention can only be determined by studying the following claims.
This application is a continuation of Ser. No. 14/081,412 which is a continuation of Ser. No. 11/871,012, filed Oct. 11, 2007, now abandoned, which is a continuation of Ser. No. 09/825,017, filed Apr. 3, 2001, now abandoned, which is a divisional application of Ser. No. 09/417,671 filed Oct. 14, 1999, now patented as U.S. Pat. No. 6,494,865.
Number | Name | Date | Kind |
---|---|---|---|
1274081 | Riethmueller | Jul 1918 | A |
1453309 | Eberly, Jr. | May 1923 | A |
1934046 | Demarchi | Nov 1933 | A |
2559474 | Son | Jul 1951 | A |
2876770 | White | Mar 1959 | A |
3179107 | Clark | Apr 1965 | A |
3400715 | Pederson | Sep 1968 | A |
3406687 | Moyer | Oct 1968 | A |
3737973 | Stawski | Jun 1973 | A |
3934590 | Campagna | Jan 1976 | A |
4060073 | Collicáet al. | Nov 1977 | A |
4270537 | Romaine | Jun 1981 | A |
4373526 | Kling | Feb 1983 | A |
4481001 | Graham et al. | Nov 1984 | A |
4583978 | Porat et al. | Apr 1986 | A |
4596556 | Morrow et al. | Jun 1986 | A |
4718463 | Jurgens, Jr. et al. | Jan 1988 | A |
4769003 | Stamler | Sep 1988 | A |
4778453 | Lopez | Oct 1988 | A |
4790824 | Morrow et al. | Dec 1988 | A |
4816024 | Sitar | Mar 1989 | A |
4883473 | Thomas | Nov 1989 | A |
4883573 | Voss et al. | Nov 1989 | A |
4886499 | Cirelli et al. | Dec 1989 | A |
4898588 | Roberts | Feb 1990 | A |
4940460 | Casey, I. et al. | Jul 1990 | A |
4941880 | Burns | Jul 1990 | A |
4955871 | Thomas | Sep 1990 | A |
4978344 | Dombrowski et al. | Dec 1990 | A |
5015235 | Crossman | May 1991 | A |
5064413 | McKinnon et al. | Nov 1991 | A |
5071353 | van der Wal | Dec 1991 | A |
5141496 | Dalto et al. | Aug 1992 | A |
5190521 | Hubbard et al. | Mar 1993 | A |
5207983 | Liebert et al. | May 1993 | A |
5222949 | Kaldany | Jun 1993 | A |
5241969 | Carson et al. | Sep 1993 | A |
5248300 | Bryant | Sep 1993 | A |
5256154 | Liebert et al. | Oct 1993 | A |
5312335 | McKinnon et al. | May 1994 | A |
5328483 | Jacoby | Jul 1994 | A |
5331954 | Rex et al. | Jul 1994 | A |
5334144 | Alchas et al. | Aug 1994 | A |
5339163 | Homma et al. | Aug 1994 | A |
5364387 | Sweeney | Nov 1994 | A |
5368578 | Covington et al. | Nov 1994 | A |
5373684 | Vacca | Dec 1994 | A |
5383851 | McKinnon, Jr. et al. | Jan 1995 | A |
5417662 | Hjertman et al. | May 1995 | A |
5431155 | Marelli | Jul 1995 | A |
5437647 | Firth et al. | Aug 1995 | A |
5466220 | Brenneman | Nov 1995 | A |
5496286 | Stiehl et al. | Mar 1996 | A |
5503627 | McKinnon et al. | Apr 1996 | A |
5505694 | Hubbard | Apr 1996 | A |
5514107 | Haber et al. | May 1996 | A |
5519984 | Beussink et al. | May 1996 | A |
5520639 | Peterson et al. | May 1996 | A |
5527288 | Gross et al. | Jun 1996 | A |
5531255 | Vacca | Jul 1996 | A |
5569089 | Signorelli | Oct 1996 | A |
5573042 | De Haen | Nov 1996 | A |
5578014 | Erez et al. | Nov 1996 | A |
5582598 | Chanoch | Dec 1996 | A |
5597530 | Smith et al. | Jan 1997 | A |
5599302 | Lilley et al. | Feb 1997 | A |
5620425 | Heffernan et al. | Apr 1997 | A |
5649912 | Peterson | Jul 1997 | A |
5665071 | Wyrick | Sep 1997 | A |
5702362 | Herold et al. | Dec 1997 | A |
5704911 | Parsons | Jan 1998 | A |
5779677 | Frezza | Jul 1998 | A |
5848991 | Gross | Dec 1998 | A |
5873856 | Hjertman et al. | Feb 1999 | A |
5879327 | Moreau DeFarges et al. | Mar 1999 | A |
5891085 | Lilley et al. | Apr 1999 | A |
5893397 | Peterson et al. | Apr 1999 | A |
5921963 | Erez et al. | Jul 1999 | A |
5957897 | Jeffrey | Sep 1999 | A |
5961495 | Walters et al. | Oct 1999 | A |
5993412 | Deily et al. | Nov 1999 | A |
6001089 | Burroughs et al. | Dec 1999 | A |
6004299 | Arai et al. | Dec 1999 | A |
6007529 | Gustafsson | Dec 1999 | A |
6036675 | Thorne et al. | Mar 2000 | A |
6053893 | Bucher | Apr 2000 | A |
6083197 | Umbaugh | Jul 2000 | A |
6090077 | Shaw | Jul 2000 | A |
6090080 | Jost et al. | Jul 2000 | A |
6090082 | King et al. | Jul 2000 | A |
6093170 | Hsu et al. | Jul 2000 | A |
6112743 | Denton | Sep 2000 | A |
6183489 | Douglas | Feb 2001 | B1 |
6200291 | Di Pietro | Mar 2001 | B1 |
6319230 | Palasis et al. | Nov 2001 | B1 |
6332875 | Inkpen | Dec 2001 | B2 |
6494865 | Alchas | Dec 2002 | B1 |
6503231 | Prausnitz et al. | Jan 2003 | B1 |
6525030 | Eriksson | Feb 2003 | B1 |
6562002 | Taylor | May 2003 | B1 |
6623457 | Rosenberg | Sep 2003 | B1 |
6808506 | Lastovich et al. | Oct 2004 | B2 |
Number | Date | Country |
---|---|---|
4127887 | Jan 1993 | DE |
0279583 | Feb 1988 | EP |
0904790 | Mar 1999 | EP |
2612401 | Sep 1988 | FR |
2206794 | Jan 1989 | GB |
2000037456 | Feb 2000 | JP |
9423777 | Oct 1994 | WO |
9501198 | Jan 1995 | WO |
9713537 | Apr 1997 | WO |
9737705 | Oct 1997 | WO |
9927986 | Jun 1999 | WO |
9934850 | Jul 1999 | WO |
Entry |
---|
Article: Dermal Immune System by Brian J. Nickoloff, MD, PhD. |
Article: Trials of Intradermal Hepatitis B Vaccines in Gambian Children by Whittle, Lamb, Ryder. |
Article: Injection of Technique Intradermal. |
Article: The Dendritic Cell System and Its Role in Immunogenicity by Ralph Steinman. |
Article: Intradermal Gene Immunization: The Possible Role of DNA Uptake in the Induction of Cellular Immunity to Viruses by: Eyal Raz et al. |
Article: Clinical Do's & Dont's—Giving Intradermal Injections by Edwina McConnell, RN, Ph.D. |
Article: Monographs of the Physiological Society No. 12: Substances Producing Pain and Itch by C.A. Keele and D. Armstrong, Pub: The Williams & Wilkins Company (1964). |
Phillips, et al., Purified Influenza Vaccine: Clinical and Serologic Response to Varying Doses and Different Routes of Immunization, Department of Medicine and Community Medicine, Univiversity of Vermont College of Medicine, Burlington, Vermont. |
Clark et al., Polyvalent Influenza Vaccine: Comparison of Jet Injection with Intradermal and Subcutaneous Syringe Methods of Administration, Oklahoma City, Oklahoma. |
“Experimental Comparison of Intradermal and Subcutaneous Vaccination with Influenza Vaccine”, Amer. J. of Med. Tech., (Nov.-Dec. 1965), vol. 31, No. 6. |
“Intradermal Influenza Immunization, Experience with Hong Kong Vaccine”, American Review of Respiratory Disease, (1971), vol. 103. |
Niculescu et al., “Efficacy of Adsorbed Trivalent Split Influenza Vaccine Administered by Intradermal Route”, received for publication Dec. 4, 1980, from Arch. Roum. Path. Exp. Microbiol., T. 40, No. 1, pp. 67-70, Janvier-Mars. 1981). |
“Efficacy of Intradermally Administered A2 Hong Kong Vaccine”, from JAMA, (Jul. 6, 1970), vol. 213, No. 1. |
Herbert et al., “Comparison of Responses to Influenza, A-New Jersey/76-A/Victoria/75 Virus Vaccine Administered Intradermally or Subcutaneously to Adults with Chronic Respiratory Disease”, J. of Infectious Diseases, (Aug. 1979), vol. 10, No. 2. |
Halperin et al., “A Comparison of the Intradermal and Subcutaneous Routes of Influenza Vaccination with A/New Jersey/76 (Swine Flu) and A/Victoria/75: Report of a Study and Review of the Literature”, Alpha, (Dec. 1979), vol. 69, No. 12. |
“Effect of Dosage and Route of Inoculation Upon Antigenicity of Inactivated Influenza Virus Vaccine (Hong Kong Strain) in Man”, from Bull. Org. mond. SantéBull. Wld Hlth Org., (1969), vol. 41, pp. 507-516. |
“Comparative Analysis of Six European Influenza Vaccines”, Eur. J. Clin. Microbiol. Infect. Dis., (1996), vol. 15, pp. 121-127. |
Renfry et al., “Morphological and Biochemical Characterization of Influenza Vaccines Commercially Available in the United Kingdom”, Vaccine, (1994), vol. 12, No. 8. |
“Influenza Immunization Policies and Practices in Japan”, Journal of Infectious Diseases, (Feb. 1980), vol. 141, No. 2. |
Parent Du Chatelet, et al., “Clinical Immunogenicity and Tolerance Studies of Liquid Vaccines Delivered by Jet-Injector and a New Single-Use Cartridge (Imule® Comparison) with Standard Syringe Injection”, Vaccine, (1997), vol. 15, No. 4. |
Polillio et al., “Does a Needleless Injection System Reduce Anxiety in Children Receiving Intramuscular Injections?”, Pediatric Primary Care Clinic, Boston City Hospital, MA, USA, Pediatr. Nurs., (Jan.-Feb. 1997), vol. 23, No. 1, pp. 46-49. (Abstract). |
Nagafuchi et al., “Intradermal Administration of Viral Vaccines”, Rev. Med. Virol., (Apr. 1998), vol. 8, No. 2, pp. 97-111. (Abstract). |
Payler et al., “Letter: Intradermal Influenza Vaccination”, Br. Med. J., (Jun. 29, 1974), vol. 2, No. 921, p. 727. (Abstract). |
“Intradermal Influenza Vaccination”, British Medical Journal, (Jun. 29, 2974). |
Smith Kline Beecham Meeting Agenda. |
Number | Date | Country | |
---|---|---|---|
20150231338 A1 | Aug 2015 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09417671 | Oct 1999 | US |
Child | 09825017 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14081412 | Nov 2013 | US |
Child | 14576347 | US | |
Parent | 11871012 | Oct 2007 | US |
Child | 14081412 | US | |
Parent | 09825017 | Apr 2001 | US |
Child | 11871012 | US |